The BioInsights Podcast
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
The BioInsights Podcast
For the many and the few: bringing ASO therapies to both mainstream and nano-rare indications
•
BioInsights
•
Season 4
•
Episode 2
Roisin McGuigan, Commissioning Editor, Nucleic Acid Insights, speaks to Stanley Crooke, Chairman, Founder and CEO, n-Lorem, about his long career and pioneering role in the antisense oligonucleotide (ASO) space, how RNA-targeting therapies are set to enter the mainstream, and his latest focus: making personalized, free-for-life ASO therapies available to nano-rare patient populations.
Could you tell me a bit about your career, from entering the oligonucleotide space to founding the n-Lorem Foundation?
How has the antisense field evolved over the time you've been active in this space, and what would you pick out as the biggest milestones to date?
You have published some very positive clinical data recently. Can you discuss some of those key clinical milestones to date, and what's next?
Where are the key opportunities as you see them to improve targeted delivery of ASO therapies?
How do you predict the ASO space will develop over the next five years, an what will be your own key priorities in that timeframe?